Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Buy” from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has been assigned a consensus rating of “Buy” from the ten ratings firms that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $20.63.

Several research analysts have recently issued reports on CATX shares. Oppenheimer reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 11th. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price on shares of Perspective Therapeutics in a report on Thursday, October 24th. Royal Bank of Canada cut their price target on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price target on the stock. Finally, UBS Group started coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective for the company.

Institutional Investors Weigh In On Perspective Therapeutics

Large investors have recently made changes to their positions in the stock. Los Angeles Capital Management LLC acquired a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at about $153,000. Hills Bank & Trust Co acquired a new stake in Perspective Therapeutics in the 3rd quarter valued at approximately $13,722,000. US Bancorp DE lifted its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after acquiring an additional 3,866 shares in the last quarter. Taylor & Morgan Wealth Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter worth approximately $400,000. Finally, Trueblood Wealth Management LLC bought a new position in shares of Perspective Therapeutics during the 3rd quarter worth approximately $217,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Price Performance

CATX stock opened at $12.19 on Tuesday. The stock has a 50 day moving average of $13.37. Perspective Therapeutics has a fifty-two week low of $2.20 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm had revenue of $0.53 million for the quarter. As a group, sell-side analysts forecast that Perspective Therapeutics will post -0.87 EPS for the current fiscal year.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.